The RAS/RAF/MEK/ERK pathway is constitutively activated in many cancers. Selumetinib (AZD6244, ARRY-142886) is an oral, potent and highly selective, allosteric MEK1/2 inhibitor with a short half-life that has ...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lxWyAk
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
This case report outlines the possibility of accelerated tooth movement with the combination of microosteoperforation and mini-screws. A 14-...
-
by Rebekah L. Rogers, Ling Shao, Kevin R. Thornton One common hypothesis to explain the impacts of tandem duplications is that whole gene ...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2juls25 via IFTTT
-
by Qi Quan, Lei Hong, Biao Chang, Ruoxi Liu, Yun Zhu, Jiang Peng, Qing Zhao, Shibi Lu Purpose The purpose of this study was to simulate and...
-
A critical step in cellular-trafficking pathways is the budding of membranes by protein coats, which recent experiments have demonstrated ca...
-
by Mark A. Valasek, Irene Thung, Esha Gollapalle, Alexey A. Hodkoff, Kaitlyn J. Kelly, Joel M. Baumgartner, Vera Vavinskaya, Grace Y. Lin, A...
-
The secondary channel (SC) of multisubunit RNA polymerases (RNAPs) allows access to the active site and is a nexus for the regulation of tra...
-
by Hellen Houlleberghs, Anne Goverde, Jarnick Lusseveld, Marleen Dekker, Marco J. Bruno, Fred H. Menko, Arjen R. Mensenkamp, Manon C. W. Sp...
-
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor British Journal of Canc...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου